NMRA Stock Analysis: Buy, Sell, or Hold?
NMRA - Neumora Therapeutics, Inc. Common Stock
$2.03
0.03 (1.76%)
▲
5d:
-0.74%
30d:
+13.13%
90d:
-30.89%
BUY
HIGH Confidence
Last Updated: January 30, 2026
Earnings: Mar 02, 2026
27d
Get Alerted When NMRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: NMRA shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: NMRA shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: NMRA is currently trading at $2.02, which is considered fair relative to its 30-day fair value range of $1.81 to $2.19.
Technical Outlook: Technically, NMRA is showing sideways momentum. Immediate support is located at $1.84, while resistance sits at $2.20.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $9.14 (+359.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NMRA is showing sideways momentum. Immediate support is located at $1.84, while resistance sits at $2.20.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $9.14 (+359.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$1.81 -
$2.19
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
80.0%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 359.4% below Wall St target ($9.14)
Fair Price Analysis
30-Day Fair Range
$1.81 -
$2.19
Current vs Fair Value
FAIR
Expected Move (7 Days)
±$0.28
(13.8%)
Support & Resistance Levels
Support Level
$1.84
Resistance Level
$2.20
Current Trend
Sideways
Fundamental Context
Forward P/E (Next Year Est.)
-2.04
Wall Street Target
$9.14
(+359.4%)
Last updated: February 02, 2026 12:39 PM ET
Data refreshes hourly during market hours. Next update: 1:39 PM
Data refreshes hourly during market hours. Next update: 1:39 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NMRA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$514 | 62 BUY |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$215 | 60 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$847 | 52 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$89 | 61 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$217 | 53 HOLD |